PTEN and metastatic neoplasm: These data indicate that patients with PTEN loss should undergo more stringent surveillance and close monitoring to allow early detection of potential recurrent/metastatic disease and be able to initiate aggressive systemic treatments combined with locoregional treatments (ie, metastectomy or other ablative therapies) and to improve overall clinical outcome.